Heron Therapeutics stock (US4277461020): Q1 2026 loss narrows as Nasdaq-listed biotech trades under USD 1

Heron Therapeutics on the Nasdaq in the United States remains in focus after reporting a narrower Q1 2026 loss in May while the low-priced biotech stock continues to trade below USD 1 per share.

Heron Therapeutics on the Nasdaq in the United States continues to attract attention from speculative biotech investors after the company reported its Q1 2026 figures on 05/11/2026 and the low-priced stock has since been trading below the USD 1 mark.

The stock is listed on the Nasdaq under the ticker HRTX and gives US-based investors exposure to a late-stage biopharmaceutical company aiming to commercialize therapies for cancer and acute-care settings, while the share price level keeps it in the category of higher-risk small caps.

According to Nasdaq price data, the stock most recently changed hands at around USD 0.87 to USD 0.89 per share on the US market, leaving the market capitalization in the low hundreds of millions of dollars and highlighting that relatively small absolute price changes can translate into notable percentage moves.

For Q1 2026, Heron Therapeutics reported a net loss per share of USD -0.04, which was slightly worse than the consensus analyst expectation of USD -0.03 per share, indicating that the company is still operating at a loss but has narrowed its deficits substantially compared with earlier stages of its development cycle.

The Q1 2026 figures were released through the companys investor relations channels and show that management continues to work on balancing revenue growth from marketed products against ongoing research and development expenses and commercialization costs in the United States.

Investors monitoring the stock on 06/01/2026 can therefore anchor their view on the combination of a sub-USD 1 share price on the Nasdaq, a Q1 2026 loss that came in slightly below consensus expectations in absolute terms, and a business model that remains firmly focused on commercializing therapies in oncology and acute care across the US market.

As of: 01.06.2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: HRTX
• Sector/industry: Biopharmaceuticals, oncology and acute-care therapeutics
• Headquarters/country: San Diego, United States
• Core markets: Primarily United States hospital and oncology treatment centers
• Key revenue drivers: Commercial sales of oncology-supportive and acute-care drugs
• Home exchange/listing venue: Nasdaq (HRTX)
• Trading currency: USD

Heron Therapeutics: core business model

Heron Therapeutics focuses on developing and marketing drug therapies that aim to improve supportive care and acute interventions for patients in oncology and hospital settings, with revenues driven mainly by uptake of its approved products in the United States healthcare system.

What banks and research houses say about Heron Therapeutics

Heron Therapeutics is covered by a range of US-focused biotech analysts, and aggregator data suggest that there is still active interest in the name despite its small market capitalization and sub-USD 1 share price, with a mix of views on the companys ability to translate its product portfolio into sustainable cash flow over the coming years.

Public consensus snapshots compiled by market data services as of late May 2026 indicate that analysts continue to model ongoing losses in the near term, but they also reflect expectations for incremental revenue growth from the commercial portfolio, making the stock a closely watched example of US-listed specialty pharma trading at a low absolute price point.

Conclusion

Heron Therapeutics remains a US Nasdaq-listed biotech with a sub-USD 1 share price following its Q1 2026 earnings release, where the company posted a modest loss that was slightly below consensus expectations in absolute terms. The analyst consensus pictures an issuer that is still loss-making but potentially able to grow revenues as its oncology-supportive and acute-care products gain traction, which keeps the stock on the radar of investors focused on higher-risk US biopharmaceutical names. How the balance between ongoing cash burn and commercial execution develops over the coming quarters is likely to be decisive for the future trading range of HRTX shares on the Nasdaq.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.